BACKGROUND AND PURPOSE: To analyze the time course of late rectal- and urinary bladder complications after brachytherapy for cervical cancer and to compare the incidence- and prevalence rates thereof. PATIENTS AND METHODS: A total of 225 patients were treated with external-beam radiotherapy (EBRT) and magnetic resonance imaging (MRI)-guided brachytherapy with or without chemotherapy. Late side effects were assessed prospectively using the Late Effects in Normal Tissue--Subjective, Objective, Management and Analytic (LENT/SOMA) scale. The parameters analyzed were time to onset, duration, actuarial incidence- (occurrence of new side effects during a defined time period) and prevalence rates (side effects existing at a defined time point). RESULTS: Median follow-up was 44 months. Side effects (grade 1-4) in rectum and bladder were present in 31 and 49 patients, 14 and 27 months (mean time to onset) after treatment, respectively. All rectal and 76 % of bladder side effects occurred within 3 years after radiotherapy. Mean duration of rectal events was 19 months; 81 % resolved within 3 years of their initial diagnosis. Mean duration of bladder side effects was 20 months; 61 % resolved within 3 years. The 3- and 5-year actuarial complication rates were 16 and 19 % in rectum and 18 and 28 % in bladder, respectively. The corresponding prevalence rates were 9 and 2 % (rectum) and 18 and 21 % (bladder), respectively. CONCLUSION: Late side effects after cervical cancer radiotherapy are partially reversible, but their time course is organ-dependent. The combined presentation of incidence- and prevalence rates provides the most comprehensive information.
BACKGROUND AND PURPOSE: To analyze the time course of late rectal- and urinary bladder complications after brachytherapy for cervical cancer and to compare the incidence- and prevalence rates thereof. PATIENTS AND METHODS: A total of 225 patients were treated with external-beam radiotherapy (EBRT) and magnetic resonance imaging (MRI)-guided brachytherapy with or without chemotherapy. Late side effects were assessed prospectively using the Late Effects in Normal Tissue--Subjective, Objective, Management and Analytic (LENT/SOMA) scale. The parameters analyzed were time to onset, duration, actuarial incidence- (occurrence of new side effects during a defined time period) and prevalence rates (side effects existing at a defined time point). RESULTS: Median follow-up was 44 months. Side effects (grade 1-4) in rectum and bladder were present in 31 and 49 patients, 14 and 27 months (mean time to onset) after treatment, respectively. All rectal and 76 % of bladder side effects occurred within 3 years after radiotherapy. Mean duration of rectal events was 19 months; 81 % resolved within 3 years of their initial diagnosis. Mean duration of bladder side effects was 20 months; 61 % resolved within 3 years. The 3- and 5-year actuarial complication rates were 16 and 19 % in rectum and 18 and 28 % in bladder, respectively. The corresponding prevalence rates were 9 and 2 % (rectum) and 18 and 21 % (bladder), respectively. CONCLUSION: Late side effects after cervical cancer radiotherapy are partially reversible, but their time course is organ-dependent. The combined presentation of incidence- and prevalence rates provides the most comprehensive information.
Authors: Maximilian P Schmid; Richard Pötter; Valentin Bombosch; Samir Sljivic; Christian Kirisits; Wolfgang Dörr; Gregor Goldner Journal: Radiother Oncol Date: 2012-06-23 Impact factor: 6.280
Authors: Stefan Lang; Christian Kirisits; Johannes Dimopoulos; Dietmar Georg; Richard Pötter Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-01 Impact factor: 7.038
Authors: Petra Georg; Stefan Lang; Johannes C A Dimopoulos; Wolfgang Dörr; Alina E Sturdza; Daniel Berger; Dietmar Georg; Christian Kirisits; Richard Pötter Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-10 Impact factor: 7.038
Authors: Jacqueline A Routledge; Meriel P Burns; R Swindell; Vincent S Khoo; Catharine M L West; Susan E Davidson Journal: Int J Radiat Oncol Biol Phys Date: 2003-06-01 Impact factor: 7.038
Authors: M P Schmid; R Pötter; P Brader; A Kratochwil; G Goldner; K Kirchheiner; A Sturdza; C Kirisits Journal: Strahlenther Onkol Date: 2012-12-21 Impact factor: 3.621
Authors: C Haie-Meder; A Kramar; P Lambin; R Lancar; P Scalliet; J Bouzy; A Gerbaulet Journal: Int J Radiat Oncol Biol Phys Date: 1994-07-30 Impact factor: 7.038
Authors: M P Schmid; B Mansmann; M Federico; J C A Dimopoulous; P Georg; E Fidarova; W Dörr; R Pötter Journal: Strahlenther Onkol Date: 2013-01-25 Impact factor: 3.621
Authors: Petra Georg; Christian Kirisits; Gregor Goldner; Wolfgang Dörr; Johann Hammer; Regina Pötzi; Daniel Berger; Johannes Dimopoulos; Dietmar Georg; Richard Pötter Journal: Radiother Oncol Date: 2009-02-23 Impact factor: 6.280
Authors: Aparna S Ramaseshan; Jessica Felton; Dana Roque; Gautam Rao; Andrea G Shipper; Tatiana V D Sanses Journal: Int Urogynecol J Date: 2017-09-19 Impact factor: 2.894
Authors: R Mazeron; J Gilmore; J Champoudry; I Dumas; J Helou; P Maroun; F Martinetti; A Gerbaulet; C Haie-Meder Journal: Strahlenther Onkol Date: 2013-11-17 Impact factor: 3.621
Authors: Peter de Boer; Maaike C G Bleeker; Anje M Spijkerboer; Agustinus J A J van de Schoot; Shandra Bipat; Marrije R Buist; Coen R N Rasch; Jaap Stoker; Lukas J A Stalpers Journal: Eur J Radiol Open Date: 2015-07-26
Authors: Peter de Boer; Agustinus J A J van de Schoot; Henrike Westerveld; Mark Smit; Marrije R Buist; Arjan Bel; Coen R N Rasch; Lukas J A Stalpers Journal: Strahlenther Onkol Date: 2017-11-03 Impact factor: 3.621